Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00829218 · ClinicalTrials.gov registry record · NA

Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)

A NA study, sponsored by Oregon Health and Science University.

Completed
Registry status
NA
Development phase
60
Enrollment target

NCT00829218 is a NA study that has completed, run by Oregon Health and Science University. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00829218, a NA study, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target

Study Summary

Objective: Randomized, double blind, placebo-controlled, crossover, clinical trial to examine the effects of the food additive glutamate (in the form of MSG) on IBS and fibromyalgia. Setting and Subjects: The Fibromyalgia Research Database at OHSU will be utilized to identify and recruit fibromyalgia patients who also have IBS to OHSU study centers. Intervention: Approximately 60 male and female subjects aged 18-75 will be placed on a 1-month glutamate-free elimination diet. Those that respond positively to the diet (we are estimating 30-40 subjects), will then be randomized to receive either a citrus drink containing 5 grams of MSG; or placebo (the citrus drink alone)on three consecutive days one week apart. The investigators are hypothesizing that those who react positively to the elimination diet will have symptom occurrence statistically more frequently when given the glutamate challenge, than when given placebo.

Interventions

  • OTHER Glutamate additive-free diet
  • OTHER Placebo diet

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2009-01
Est. Completion 2010-05
Phase NA

What the Registry Record Tells You About NCT00829218

The ClinicalTrials.gov registry entry for NCT00829218 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Glutamate additive-free diet is the first listed.

NCT00829218 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00829218 about?

NCT00829218 is a clinical study titled "Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)". Objective: Randomized, double blind, placebo-controlled, crossover, clinical trial to examine the effects of the food additive glutamate (in the form of MSG) on IBS and fibromyalgia. Setting and Subjects: The Fibromyalgia Research Database at OHSU will be utilized to identify and recruit fibromyalg...

What is the current status of trial NCT00829218?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2009-01. Estimated completion is 2010-05.

What interventions are being tested in trial NCT00829218?

The interventions under investigation include: Glutamate additive-free diet (OTHER), Placebo diet (OTHER).

Who is sponsoring clinical trial NCT00829218?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.